⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Alnylam Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Alnylam Pharmaceuticals
↗Cambridge, USA
Alnylam Pharmaceuticals is a leading biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics. The company focuses on the discovery, development, and commercialization of novel medicines that silence disease-causing genes, addressing significant unmet medical needs in rare and prevalent diseases.
Headquartered in Cambridge, Massachusetts, Alnylam has successfully transitioned from a research-focused organization to a commercial-stage company with multiple FDA-approved RNAi products. The company is currently executing its 'Alnylam 2030' strategy, aiming to achieve global leadership in ATTR amyloidosis and drive sustainable growth through a deep pipeline of innovative therapies.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:RNA interference (RNAi) therapeutics
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$4.29B
Founded:2002
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:ALNY
Market Cap:$39.8B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:RNAi / siRNA
Active Trials:90
Trial Phases:-
FDA Approvals:6
EMA Approvals:6
CORPORATE STRUCTURE
Key Partnerships:Novartis (Leqvio), Sanofi (Qfitlia/fitusiran), Regeneron (cemdisiran), Roche (hypertension program), Viz.ai (ATTR-CM care coordination)
COMPETITION
Position:Leader
Competitors:Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, BridgeBio Pharma, Pfizer
LEADERSHIP
Key Executives:
Yvonne Greenstreet - CEO
Pushkal Garg - Chief Medical Officer
Kevin Fitzgerald - Chief Scientific Officer
Scientific Founders:Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, Phillip Zamore
Board Members:Amy Schulman (Chair), Olivier Brandicourt, Margaret Hamburg
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Alnylam Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.